Overview

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Status:
Completed
Trial end date:
2001-10-01
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of amifostine, carboplatin and cyclophosphamide, followed by peripheral stem cell transplantation, in treating patients with epithelial ovarian cancer or primary peritoneal cancer.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Chicago
Treatments:
Amifostine
Carboplatin
Cyclophosphamide
Criteria
DISEASE CHARACTERISTICS: Histologically proven ovarian epithelial cancer or primary
peritoneal carcinoma No tumors of low malignant potential Chemotherapy sensitive disease
Relapse greater than 6 months after complete response to chemotherapy Partial response to
most recent chemotherapy No more than 3 prior chemotherapy regimens Evidence of refractory
or recurrent disease other than elevated CA-125 after primary surgery or chemotherapy;
persistent disease need not be still present No brain metastases

PATIENT CHARACTERISTICS: Age: 65 and under Performance status: GOG 0 or 1 Life expectancy:
Not specified Hematopoietic: WBC greater than 2500/mm3 Platelet count greater than
100,000/mm3 Hepatic: Bilirubin normal Renal: Creatinine clearance at least 50 mL/min
Cardiovascular: Normal radionuclide cardiac scan with ejection fraction greater than 45% OR
Normal left ventricular function by echocardiogram OR Cardiac clearance by Cardiology
service Pulmonary: DLCO greater than 50% predicted Other: Not pregnant Hepatitis B and C
negative HIV-1 negative

PRIOR CONCURRENT THERAPY: See Disease Characteristics